CA-ANDERSEN-GLOBAL
24.2.2021 10:59:10 CET | Business Wire | Pressemeddelelse
Efter den hurtige udvidelse i Afrika forener Andersen Global nu sine afrikanske medlemsfirmaer under brandet ”Andersen”. Som en del af denne overgang vil fem tidligere samarbejdspartnere blive medlemsfirmaer af Andersen Global, hvorved platformen i Afrika styrkes. Offentliggørelsen følger i hælene på implementeringen af Andersen-brandet af det stiftende amerikanske medlemsfirma i 2019 og medlemsfirmaer i Europa, Latinamerika og Mellemøsten i 2020.
Andersen Global-medlemsfirmaer i Nigeria og Kenya, som tidligere opererede under brandet ”Andersen Tax”, vil nu overgå til det kendte brand ”Andersen”. Tidligere samarbejdspartnere i Sydafrika (Tabacks), Tunesien (Jelil Bouraoui & Associates) samt Mauritius og Seychellerne (ATax Advisors) vil ligeledes implementere det nye Andersen-brand. Andersen Global byder også medlemsfirmaer på Elfenbenskysten (Mondon Conseil) og i Mozambique (Isálcio Mahanjane Advogado & Associados) velkommen.
At arbejde under et kendt brand demonstrerer regionens evne til at tilbyde ukomplicerede tjenester globalt sammen med de andre Andersen Global-medlemsfirmaer. Andersen Global er via sine medlemsfirmaer og samarbejdspartnere repræsenteret i 45 lande på kontinentet, indbefattet juridiske tjenester i 41 lande.
”I de sidste mange år har vores platform i Afrika haft en høj prioritet i overensstemmelse med vores forpligtelse over for kundeservice og tilvejebringelsen af ukomplicerede skatte- og juridiske tjenester globalt. Efterhånden som økonomien og markederne fortsætter med at ændre sig og blive mere globale, er vores organisations behov for omfattende løsninger på tværs af landegrænser blevet vigtigere. Igennem vores udvidelsesbestræbelser og foreningen af vores afrikanske medlemsfirmaer under et kendt brand, har vi opnået vores mål om at have det største juridiske fodaftryk på kontinentet” udtalte Mark Vorsatz, Andersen Global bestyrelsesformand og adm. direktør hos Andersen. ”Vi forbliver forpligtet over for at være et af de mest betydningsfulde skatte- og advokatfirmaer når det gælder medarbejderstab, geografisk dækning og – vigtigst af alt – kvalitet”.
For yderligere at styrke sin ledelsesstruktur i regionen, har organisationens afrikanske bestyrelse valgt Jelil Bouraoui som virksomhedsleder hos Andersen i Tunesien til at repræsentere regionen i bestyrelsen hos Andersen Global. Derudover vil Olaleye Adebiyi, virksomhedsleder hos Andersen i Nigeria, og Derrick Kaufmann, virksomhedsleder hos Andersen i Sydafrika, tjene som assisterende virksomhedsledere i regionen. Jelil, Olaleye og Derrick vil arbejde tæt sammen for at administrere organisationen i Afrika og støtte regionens fremtidige udvidelsesbestræbelser.
Grundlaget for Andersens globale platform går helt tilbage til 2002, hvor 23 tidligere Arthur Andersen-partnere oprettede et firma, der kun beskæftigede sig med skat, WTAS LLC, som efterfulgtes af Andersen Global (tidligere WTAS Global) i 2013. Det efterfølgende år tog det amerikanske medlemsfirma brandet ”Andersen Tax” til sig, efterfulgt af medlemsfirmaer i Latinamerika, Europa og Afrika. Andersen Tax debuterede i Nigeria i 2017 og i Kenya i 2018, og regionen er siden blevet udvidet til i dag at omfatte mere end 65 lokationer, 1.000 medarbejdere inden for skat og jura og næsten 200 partnere.
I løbet af det næste år fortsætter medlemsfirmaer i Canada og Israel med at implementere det fælles Andersen-brand, mens Andersen Global fortsætter med at udvide på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 7.000 eksperter globalt og er repræsenteret på mere end 254 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210224005456/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum